Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Buck Institute for Age Research and Q Therapeutics have announced an agreement to collaborate on novel routes to combat Parkinson's disease.
Subscribe to our email newsletter
The Buck Institute and Q Therapeutics will use their expertise in differentiating stem cells to provide key cell types needed to study Parkinson’s disease. These neural-lineage cell lines will be used to further research aimed at the use of various stem and progenitor cells as a potential treatment for Parkinson’s disease.
Deborah Eppstein, president and CEO of Q Therapeutics, said: “We look forward to furthering development of cell therapy products to treat Parkinson’s disease by leveraging the expertise of both the Buck Institute and Q Therapeutics.”